Last reviewed · How we verify
FF via ELLIPTA DPI
FF (fluticasone furoate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
FF (fluticasone furoate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | FF via ELLIPTA DPI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and reduced airway inflammation. The ELLIPTA DPI (dry powder inhaler) is a delivery device designed to optimize lung deposition of the drug. This combination is used to control asthma and COPD symptoms by reducing airway obstruction and inflammation.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Oral candidiasis
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma (PHASE2)
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design (PHASE4)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF via ELLIPTA DPI CI brief — competitive landscape report
- FF via ELLIPTA DPI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI